Hypercoagulable states

Last updated: October 12, 2023

Summarytoggle arrow icon

A hypercoagulable state, i.e., thrombophilia, is a predisposition to forming blood clots. Depending on the etiology, one or more factors of the Virchow triad (stasis, hypercoagulability, endothelial damage) may be involved. Hypercoagulability may be acquired or inherited and can affect veins and/or arteries. It leads to an increased risk of developing venous thromboembolism (VTE), which most commonly manifests as deep venous thrombosis of the lower extremities or pulmonary embolism. Arterial involvement increases the risk of myocardial infarction, stroke, and spontaneous abortion. Evaluation for hypercoagulability includes assessment of potential risk factors (e.g., immobilization, smoking, oral contraceptive use, and malignancy) and laboratory tests to assess anomalies of the clotting cascade (e.g., factor V Leiden, antiphospholipid antibody syndrome). Treatment is based on the underlying condition and typically includes a reduction of risk factors and/or the administration of anticoagulants.

Definitiontoggle arrow icon

Etiologytoggle arrow icon

The development of thromboembolic disease is multifactorial and more commonly triggered by traditional risk factors than by inherited or acquired thrombophilia. A single patient may have multiple underlying conditions or risk factors (both hereditary and acquired) which can lead to a higher cumulative risk of thromboembolism. [6]

Traditional risk factors for thromboembolic disease [1][2][3]

Hereditary causes of hypercoagulability [6][8]

Acquired causes of hypercoagulability [6][12][13][14]

Clinical featurestoggle arrow icon

Clinical features of thromboembolism

These typically depend on the location of thromboembolism, the vasculature involved, and the underlying condition.

Clinical features suggestive of underlying thrombophilia [1][6]

Consider antiphospholipid syndrome in young patients with stroke with no cardiovascular risk factors.

Pathophysiologytoggle arrow icon

Underlying mechanisms vary depending on whether thrombophilia is hereditary or acquired.

Hereditary thrombophiliatoggle arrow icon

Pathophysiology of hereditary thrombophilia [17][18][19]
Defect Pathophysiology Prevalence in general population

Activated protein C resistance (APC-R)

Factor V Leiden [20]

  • Heterozygosity: ∼ 5%
  • Homozygosity: < 1%
Elevated factor VIII
  • ∼ 5%
Prothrombin mutation
  • ∼ 3%

Protein S deficiency

  • ∼ 1%
Protein C deficiency
  • < 1%
Antithrombin III deficiency
  • ∼ 0.1%


∼ 5–7%

Acquired thrombophiliatoggle arrow icon

Pathophysiology of acquired thrombophilia [21][22][23]
Etiology Pathophysiology
  • Results in decreased venous blood flow, immobilization (blood stasis), and release of tissue factor (hypercoagulability) → increased clotting




Antiphospholipid syndrome

Nephrotic syndrome

  • Loss of plasma antithrombin in urine and an increase in blood viscosity due to extravasation of fluid from albumin loss in urine

Oral contraceptive pills (OCPs) or hormone replacement therapy (HRT)

Heparin-induced thrombophilia
Advanced age [22]
  • Progressive endothelial damage
  • Increase in pro-clotting factors without a concomitant increase in protein C
  • Increase in other pro-clotting comorbidities (e.g., malignancy)
  • Decreased physical activity

Diagnosticstoggle arrow icon

General principles

  • Most thrombophilias are identified following a thromboembolic event, the majority of which are multifactorial, involving a combination of transient and chronic risk factors.
  • Thrombophilia testing is unnecessary in most cases.
  • Perform a detailed clinical evaluation to identify patients who may benefit from additional testing.
  • See “Prevention” for screening recommendations in asymptomatic patients.

Routine investigations

Often performed as part of the initial workup of a thromboembolic event and can help identify some predisposing conditions.

Thrombophilia testing [1][24]

Thrombophilia testing is only warranted in select cases, however, there are no universally agreed-upon indications. The final decision on specific investigations is usually done by a specialist based on a detailed individual assessment, clinical judgment, and whether results will alter management [1][25]

Patient selection

Thrombophilia workup can safely be deferred in most patients with a provoked VTE, e.g., due to a strong trigger. [1]

Laboratory studies [6][8][16][26]

Consider the following based on clinical suspicion as guided by a specialist:

Timing of investigations

  • Not indicated during an acute event [1]
  • Only conduct once initial anticoagulation therapy has been completed.
  • Ensure there has been a sufficient duration since the completion of therapy. [1]

Screening for occult malignancy [15][27][28]

Treatmenttoggle arrow icon

General principles

  • A diagnosis of thrombophilia seldom alters the management of acute thromboembolic events, except in select cases (see “Acute management of specific thrombophilias”). [1]
  • Most patients are diagnosed following a thromboembolic event and long-term management consists mostly of secondary prevention.
    • Options include anticoagulation and reduction of modifiable risk factors.
    • Recommendations vary depending on the type and extent of thromboembolism and patient characteristics (see conditions in “Standard management of thromboembolic disease”).
  • Management of asymptomatic patients consists primarily of nonpharmacologic prophylaxis against thromboembolic events; see “Prevention” for details.

Weigh risks and benefits of anticoagulation individually for patients with increased bleeding risk, e.g., risk of falls, severe hypertension.

Standard management of thromboembolic diseases

Arterial thromboembolism

Venous thromboembolism

Acute management of specific thrombophilias

Consult a hematologist to tailor treatment according to individual patient risks.

Preventiontoggle arrow icon

This section describes screening for asymptomatic patients at risk of thrombophilia and primary prevention measures for thromboembolism in patients with positive screening or risk factors (see “Treatment” for secondary prevention measures). Standard VTE prophylaxis is indicated in select circumstances regardless of thrombophilia status (e.g., postoperative status, prolonged immobilization or hospitalization, active malignancy).

Indications for thrombophilia screening [6][26][33]

Screening for thrombophilia in asymptomatic patients may be indicated in patients at high risk and, depending on the results, a specialist may choose to start prophylaxis. Possible indications for screening include:

There is no clear guidance for thrombophilia screening and VTE prophylaxis for asymptomatic patients; decisions should be guided by a specialist. [33]

Management of asymptomatic thrombophilia

Primary prevention is generally not recommended. However, some high-risk patients may benefit from managing modifiable risk factors and primary prophylaxis measures. [8][26][33]

Primary prophylactic measures are also recommended in the absence of laboratory findings of thrombophilia if patients have a strong family history of thrombophilia. [26]

Avoid OCPs in patients who are carriers of Factor V Leiden. [34]

Referencestoggle arrow icon

  1. Colman RW. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Lippincott Williams & Wilkins ; 2006
  2. Den Boer NC, Van der Heiden C, Leijnse B, Souverijn JHM. Clinical chemistry: an overview . Plenum Press ; 1989
  3. Kumar A, Afreen S, Mohd Yusuf, Gupta A. Mechanism and pathophysiology of activated protein C-related factor V leiden in venous thrombosis. Asian Journal of Transfusion Science. 2012; 6 (1): p.47.doi: 10.4103/0973-6247.95053 . | Open in Read by QxMD
  4. Gottlieb JL. Activated Protein C Resistance, Factor V Leiden, and Central Retinal Vein Occlusion in Young Adults. Arch Ophthal. 1998; 116 (5): p.577.doi: 10.1001/archopht.116.5.577 . | Open in Read by QxMD
  5. Connors JM. Thrombophilia Testing and Venous Thrombosis. N Engl J Med. 2017; 377 (12): p.1177-1187.doi: 10.1056/nejmra1700365 . | Open in Read by QxMD
  6. Investigators TBS. Bridging anticoagulation: is it needed when warfarin is interrupted around the time of a surgery or procedure?. Circulation. 2012; 125 (12): p.e496-e498.doi: 10.1161/CIRCULATIONAHA.111.084517 . | Open in Read by QxMD
  7. Bauer KA. Management of thrombophilia. J Thromb Haemost. 2003; 1 (7): p.1429-1434.doi: 10.1046/j.1538-7836.2003.00274.x . | Open in Read by QxMD
  8. Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018; 378 (21): p.2010-2021.doi: 10.1056/nejmra1705454 . | Open in Read by QxMD
  9. Chaturvedi S, McCrae KR. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 2017; 31 (6): p.406-417.doi: 10.1016/j.blre.2017.07.006 . | Open in Read by QxMD
  10. Liu X, Chen Y, Ye C, et al. Hereditary thrombophilia and recurrent pregnancy loss: a systematic review and meta-analysis. Hum Reprod. 2021; 36 (5): p.1213-1229.doi: 10.1093/humrep/deab010 . | Open in Read by QxMD
  11. Mignot E, Lammers GJ, Ripley B, et al. The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias. Arch Neurol. 2002; 59 (10): p.1553.doi: 10.1001/archneur.59.10.1553 . | Open in Read by QxMD
  12. Colucci G, Tsakiris DA. Thrombophilia screening revisited: an issue of personalized medicine. J Thromb Thrombolysis. 2020; 49 (4): p.618-629.doi: 10.1007/s11239-020-02090-y . | Open in Read by QxMD
  13. Fitridge R, Thompson M. Mechanisms of Vascular Disease. The University of Adelaide, Barr Smith Press ; 2011
  14. Carroll BJ, Piazza G. Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?. Vasc Med. 2018; 23 (4): p.388-399.doi: 10.1177/1358863x18755927 . | Open in Read by QxMD
  15. Kakkos SK, Gohel M, Baekgaard N, et al.. European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg. 2021; 61 (1): p.9-82.doi: 10.1016/j.ejvs.2020.09.023 . | Open in Read by QxMD
  16. Parakh RS, Sabath DE. Venous Thromboembolism: Role of the Clinical Laboratory in Diagnosis and Management.. The journal of applied laboratory medicine. 2019; 3 (5): p.870-882.doi: 10.1373/jalm.2017.025734 . | Open in Read by QxMD
  17. Van Es N, Le Gal G, Otten H-M, et al. Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism. Ann Intern Med. 2017; 167 (6): p.410.doi: 10.7326/m17-0868 . | Open in Read by QxMD
  18. Carrier M, Lazo-Langner A, Shivakumar S, et al. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med. 2015; 373 (8): p.697-704.doi: 10.1056/nejmoa1506623 . | Open in Read by QxMD
  19. Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016; 41 (1): p.154-164.doi: 10.1007/s11239-015-1316-1 . | Open in Read by QxMD
  20. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Oral Contraceptives and the Risk of Venous Thrombosis. N Engl J Med. 2001; 344 (20): p.1527-1535.doi: 10.1056/nejm200105173442007 . | Open in Read by QxMD
  21. Previtali E, Paolo B. Risk factors for venous and arterial thrombosis. Blood Transfus. 2011: p.120-138.doi: 10.2450/2010.0066-10 . | Open in Read by QxMD
  22. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Advances. 2020; 4 (19): p.4693-4738.doi: 10.1182/bloodadvances.2020001830 . | Open in Read by QxMD
  23. Ageno W, Farjat A, Haas S, et al. Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE. Research and Practice in Thrombosis and Haemostasis. 2021; 5 (2): p.326-341.doi: 10.1002/rth2.12482 . | Open in Read by QxMD
  24. Tritschler T, Wells PS. Extended therapy for unprovoked venous thromboembolism: when is it indicated?. Blood Advances. 2019; 3 (3): p.499-499.doi: 10.1182/bloodadvances.2018026518 . | Open in Read by QxMD
  25. Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Curr Opin Hematol. 2015; 20 (5): p.437-444.doi: 10.1097/MOH.0b013e3283634443 . | Open in Read by QxMD
  26. Esmon CT. Basic Mechanisms and Pathogenesis of Venous Thrombosis. Blood Rev. 2009; 23 (5): p.225–229.doi: 10.1016/j.blre.2009.07.002 . | Open in Read by QxMD
  27. Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res. 2010; 126 (1): p.5-11.doi: 10.1016/j.thromres.2010.01.045 . | Open in Read by QxMD
  28. Anderson FA, Spencer FA. Risk Factors for Venous Thromboembolism. Circulation. 2003; 107 (23_suppl_1).doi: 10.1161/01.cir.0000078469.07362.e6 . | Open in Read by QxMD
  29. Mehta R, Shapiro AD. Plasminogen deficiency. Haemophilia. 2008; 14 (6): p.1261-1268.doi: 10.1111/j.1365-2516.2008.01825.x . | Open in Read by QxMD
  30. Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 2013; 122 (24): p.3892-3898.doi: 10.1182/blood-2013-05-498311 . | Open in Read by QxMD
  31. Gordeuk VR. Sickle cell vaso-occlusion: the clot thickens. Blood. 2020; 135 (20): p.1726-1727.doi: 10.1182/blood.2020005034 . | Open in Read by QxMD
  32. Armstrong EM, Bellone JM, et al. Acquired Thrombophilia. J Pharm Pract. 2014; 27 (3): p.234-242.doi: 10.1177/0897190014530424 . | Open in Read by QxMD
  33. Primignani M, La Mura V. Diagnosis of thrombophilia/prothrombotic conditions in patients with liver disease. Clin Liver Dis (Hoboken). 2014; 3 (6): p.126-128.doi: 10.1002/cld.342 . | Open in Read by QxMD
  34. Bazzan M, Vaccarino A, Marletto F. Systemic lupus erythematosus and thrombosis. Thromb J. 2015; 13 (1).doi: 10.1186/s12959-015-0043-3 . | Open in Read by QxMD

Icon of a lock3 free articles remaining

You have 3 free member-only articles left this month. Sign up and get unlimited access.
 Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer